SCHEMBL31689529

SCHEMBL31689529

N[C@@H](Cc1cccc(NS(=O)(=O)c2ccccc2)c1)C(=O)O

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 7/20 0.64
NOS3 P29474 2/20 0.55
NOS1 P29475 2/20 0.55
NOS2 P35228 2/20 0.55
PTGES O14684 1/20 0.55
SLC7A5 Q01650 4/20 0.54
ALPI P09923 1/20 0.54
PKM P14618 1/20 0.54
PTGS1 P23219 1/20 0.54
XIAP P98170 1/20 0.54
GRIA2 P42262 1/20 0.49
IL1RN P18510 1/20 0.49
KEAP1 Q14145 1/20 0.49
ERAP1 Q9NZ08 1/20 0.49
LIMK1 P53667 1/20 0.48
LIMK2 P53671 1/20 0.48
CASR P41180 1/20 0.48
MEN1 O00255 1/20 0.48
CRHBP P24387 1/20 0.48
KMT2A Q03164 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7359876 0.93 HTR6 (0.55) HTR6NOS3NOS1NOS2PTGES
SCHEMBL31689553 0.89 PKM (0.53) HTR6NOS3NOS1NOS2PTGES
SCHEMBL20715878 0.85 HDAC1 (0.62) HTR6SLC7A5ALPIPKMPTGS1
SCHEMBL19234913 0.85 HDAC1 (0.62) HTR6SLC7A5ALPIPKMPTGS1
SCHEMBL5078465 0.85 HDAC1 (0.62) HTR6SLC7A5ALPIPKMPTGS1
SCHEMBL31689432 0.84 NOS3 (0.61) NOS3NOS1NOS2SLC7A5ALPI
SCHEMBL31689461 0.83 PGR (0.54) HTR6MEN1KMT2A
SCHEMBL22689927 0.82 NOS3 (0.55) NOS3NOS1NOS2SLC7A5ALPI
SCHEMBL22689929 0.82 NOS3 (0.55) NOS3NOS1NOS2SLC7A5ALPI
SCHEMBL22689783 0.82 NOS3 (0.55) NOS3NOS1NOS2SLC7A5ALPI

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250339388-A1 PHENYLALANINE-BASED LAT1 INHIBITORS AND USES THEREOF MAXYMUNE THERAPEUTICS INC (US) 2025-11-06 US disclosed
US-20250319046-A1 PHENYLALANINE-BASED LAT1 INHIBITORS AND USES THEREOF MAXYMUNE THERAPEUTICS INC (US) 2025-10-16 US disclosed
US-12427124-B1 Phenylalanine-based LAT1 inhibitors and uses thereof Maxymune Therapeutics, Inc. (US) 2025-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250339388-A1 PHENYLALANINE-BASED LAT1 INHIBITORS AND USES THEREOF SLC43A1, SLC7A1, SLC1A5 HTR6 3029/4885NOS3 2165/4885NOS1 1158/4885
US-12427124-B1 Phenylalanine-based LAT1 inhibitors and uses thereof SLC43A1, SLC7A1, SLC1A5 HTR6 3029/4885NOS3 2165/4885NOS1 1158/4885
US-20250319046-A1 PHENYLALANINE-BASED LAT1 INHIBITORS AND USES THEREOF SLC43A1, SLC7A1, SLC1A5 HTR6 3029/4885NOS3 2165/4885NOS1 1158/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.